Select Clinical Trial
Protocol Number: ImmunoGen/GOG 3045
Protocol Title: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Eligibility: Women ≥ 18 years of age with a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. Patients must have platinum-resistant disease.
Contact Information: (910) 715-2200